5th Molecular Imaging in Drug Discovery & Development (MI2011)

Venue: Philadelphia

Location: Philadelphia, Pennsylvania, United States

Event Date/Time: Mar 07, 2011 End Date/Time: Mar 08, 2011
Report as Spam


Dear Colleague,

The obstacles to successful drug discovery and development are numerous and well appreciated. In discovery, from target identification through lead optimization and validation, and in development, from first-in-man studies through large registration trials, inefficiencies and uncertainties complicate even well funded efforts by sophisticated and industrious scientists and clinicians. Despite huge outlays by the worldwide pharmaceutical research enterprise, the number of new chemical entities brought to market has actually declined in recent years, even as the cost of developing them has increased significantly.

Against this backdrop, biomedical imaging is poised to play an increasingly powerful role in enhancing the efficiency of the drug discovery and development process. Multiple modalities, including optical imaging, ultrasound, nuclear imaging (both positron and single photon tomography), x-ray computed tomography, and the many flavors of magnetic resonance imaging are all being integrated ever more fundamentally in the various phases of drug discovery and development. In CNS, oncology, rheumatology/inflammation, and many other clinical settings, imaging is proving invaluable.

The 5th Molecular Imaging in Drug Discovery and Development Conference will be held March 7-8, 2011, in Philadelphia, PA. Sessions for the conference are:

Session I - Novel Imaging Methods & Technology
Session II - Imaging Applications in Pre Clinical Drug Discovery
Session III - Imaging Biomarkers for Clinical Drug Development
Session IV - Imaging Applications in Oncology
Session V - Multi Modality Imaging

This conference will survey a wide range of topics in the field, from the latest advances in the modalities themselves to their application to cutting-edge preclinical and clinical problems. Presentations will be made from numerous distinguished contributors to the field’s advancement on both scientific topics and subjects of interest to the regulatory, data management and investment communities.

Kind Regards,

2011 Imaging Conference Advisory Committee


United States